On June 28th, the National Medical Insurance Administration announced the "2024 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog Adjustment Work Plan". This year's work process is still divided into five stages: preparation, application, expert review, negotiation, and announcement of results. The application will be officially launched on July 1st, and efforts will be made to complete the negotiations and announce the results in November. That is to say, today (July 1st), the adjustment of the medical insurance drug catalog in 2024 has officially started, and eligible pharmaceutical companies can start submitting application materials. According to the rules, newly approved drugs between January 1, 2019 and June 30, 2024 are eligible to participate. According to incomplete industry statistics, there are nearly 200 innovative drugs that meet the conditions for medical insurance negotiations in 2024. Both Golixitinib (trade name: Gorizol) and Shuwotinib (trade name: Shuwozhe) from Dizhe Pharmaceuticals are eligible, with Golixitinib approved for sale on June 18th and the first batch of prescriptions issued nationwide on June 27th. The most concerning aspect of the annual adjustment of the medical insurance catalog is the negotiation process that has given rise to the phenomenon of "soul bargaining". Previously, the National Medical Insurance Administration introduced that in order to stabilize enterprise expectations, this year's renewal rules and bidding rules are basically consistent with previous years. Wu Qingyi said that for cancer drugs, medical insurance mainly solves the problem of payment. By incorporating medical insurance, we can maximize patient accessibility and make "the world's first" to serve Chinese patients. The negotiation rules for medical insurance are undergoing some changes, such as milder renewal rules and more emphasis on breakthrough innovation. The direction trend is good, and products that truly innovate at the source should receive more reasonable returns, encouraging enterprises and researchers. The newly approved Golixitinib in June is the world's first and only highly selective JAK1 inhibitor for the treatment of PTCL, used as a monotherapy for adult patients with recurrent or refractory peripheral T-cell lymphoma (r/r PTCL) who have received at least first-line systemic treatment in the past. Regarding the expected negotiation price of this globally pioneering drug, Wu Qingyi did not directly respond. She said, "In terms of price, the newly entered blood tumor drugs into medical insurance in the past two years have negotiated and signed prices of about 100000 yuan/year, with the highest being over 200000 yuan/year. We definitely hope to negotiate in this range or even higher directions. The specific price depends on the negotiation situation." It is worth noting that this year's adjustment of the medical insurance catalog will not only add negotiated drugs that have not been guaranteed market supply according to the agreement in the case of being transferred out, but will also add clauses on ensuring drug supply in this year's agreement and include them in assessment management, urging pharmaceutical companies to do a good job in the market after being included in the medical insurance catalog through negotiations. Supply to better protect the rights and interests of insured patients. Regarding the above rules, Zhang Xiaolin, founder, chairman, and CEO of Dieter Pharmaceuticals, stated: "Dieter Pharmaceuticals' partner is WuXi AppTec's comprehensive pharmaceutical industry, and we have confidence in its quality. At the same time, our internal team is specifically responsible for quality control. At the same time, the company is building its own factory, which will be capped next month. Ultimately, we will achieve supply chain diversification and cannot get stuck on the same path. In addition to the domestic market, going overseas is also an important commercialization path for domestic innovative drugs in the past two years.". According to the financial report of Dizhe Pharmaceuticals, currently, the relevant indications for both domestically approved products have been awarded "Fast Track Certification" and "Breakthrough Therapy Certification" by the FDA. Zhang Xiaolin believes that going abroad is definitely an important direction for the development of pharmaceutical companies. The United States still has a large market, and the company is actively communicating, hoping that related products can be approved as soon as possible to meet the needs of patients. However, it cannot be ignored that the current US pharmaceutical industry is also facing new environmental changes. Previously, the US also had many advantages in pricing. Now, according to some authoritative US institutions, it is estimated that the price of drugs in the first wave of negotiations in the US will decrease by 50% to 60%. The overseas market is important, but it is no longer as important as before. China must have its own internal market to support enterprises. Without the support of its domestic market, it is impossible to form a strong industry Zhang Xiaolin emphasized. (Lai Xin She)